Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Determination of benchmark concentrations and their statistical uncertainty for cytotoxicity test data and functional in vitro assays

  • Krebs, Alice
  • Nyffeler, Johanna
  • Karreman, Christiaan
  • Schmidt, Béla Z.
  • Kappenberg, Franziska
  • Mellert, Jan
  • Pallocca, Giorgia
  • Pastor Maeso, Manuel
  • Rahnenführer, Jörg
  • Leist, Marcel
Many toxicological test methods, including assays of cell viability and function, require an evaluation of concentration-response data. This often involves curve fitting, and the resulting mathematical functions are then used to determine the concentration at which a certain deviation from the control value occurs (e.g. a decrease of cell viability by 15%). Such a threshold is called the benchmark response (BMR). For a toxicological test, it is often of interest to determine the concentration of test compound at which a pre-defined BMR of e.g. 10, 25 or 50% is reached. The concentration at which the modelled curve crosses the BMR is called the benchmark concentration (BMC). We present a user-friendly, web-based tool (BMCeasy), designed for operators without programming skills and profound statistical background, to determine BMCs and their confidence intervals. BMCeasy allows simultaneous analysis of viability plus a functional test endpoint, and it yields absolute BMCs with confidence intervals for any BMR. Besides an explanation of the algorithm underlying BMCeasy, this article also gives multiple examples of data outputs. BMCeasy was used within the EU-ToxRisk project for preparing data packages that were submitted to regulatory authorities, demonstrating the real-life applicability of the tool., This work was supported by the BMBF, EFSA, the DK-EPA, and the DFG (Konstanz Research School of Chemical Biology; KoRS-CB). It has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs). We are grateful to collaborators R. von Hellfeld and T. Braunbeck (University of Heidelberg), and H. Vrieling and J. Boei (Leiden University Medical Center) of the EU-ToxRisk con-sortium for providing the experimental data. We are indebted to S. Förster for triggering this work and to other colleagues for in-sightful discussions.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

New approach methods (NAMs) supporting read-across: Two neurotoxicity AOP-based IATA case studies

  • Van der Stel, Wanda
  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Van de Water, Bob
Read-across approaches are considered key in moving away from in vivo animal testing towards addressing data-gaps using new approach methods (NAMs). Ample successful examples are still required to substantiate this strategy. Here we present and discuss the learnings from two OECD IATA endorsed read-across case studies. They involve two classes of pesticides – rotenoids and strobilurins – each having a defined mode-of-action that is assessed for its neurological hazard by means of an AOP-based testing strategy coupled to toxicokinetic simulations of human tissue concentrations. The endpoint in question is potential mitochondrial respiratory chain mediated neurotoxicity, specifically through inhibition of complex I or III. An AOP linking inhibition of mitochondrial respiratory chain complex I to the degeneration of dopaminergic neurons formed the basis for both cases but was deployed in two different regulatory contexts. The two cases also exemplify several different read-across concepts: analogue versus category approach, consolidated versus putative AOP, positive versus negative prediction (i.e., neurotoxicity versus low potential for neurotoxicity), and structural versus biological similarity. We applied a range of NAMs to explore the toxicodynamic properties of the compounds, e.g., in silico docking as well as in vitro assays and readouts – including transcriptomics – in various cell systems, all anchored to the relevant AOPs. Interestingly, although some of the data addressing certain elements of the read-across were associated with high uncertainty, their impact on the overall read-across conclusion remained limited. Coupled to the elaborate regulatory review that the two cases underwent, we propose some generic learnings of AOP-based testing strategies supporting read-across., This work was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 681002 (EU-ToxRisk). Parts of this work contributed to two IATA Case Studies Projects “Identification and characterization of parkinsonian hazard liability of deguelin by an AOP-based testing and read across approach” and “Mitochondrial complex-III-mediated neurotoxicity of azoxystrobin – Read-across to other strobilurins” (van der Stel et al., 2020b; Bennekou et al., 2020).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Flame: an open source framework for model development, hosting, and usage in production environments

  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Sanz, Ferran
This article describes Flame, an open source software for building predictive models and supporting their use in production environments. Flame is a web application with a web-based graphic interface, which can be used as a desktop application or installed in a server receiving requests from multiple users. Models can be built starting from any collection of biologically annotated chemical structures since the software supports structural normalization, molecular descriptor calculation, and machine learning model generation using predefined workflows. The model building workflow can be customized from the graphic interface, selecting the type of normalization, molecular descriptors, and machine learning algorithm to be used from a panel of state-of-the-art methods implemented natively. Moreover, Flame implements a mechanism allowing to extend its source code, adding unlimited model customization. Models generated with Flame can be easily exported, facilitating collaborative model development. All models are stored in a model repository supporting model versioning. Models are identified by unique model IDs and include detailed documentation formatted using widely accepted standards. The current version is the result of nearly 3 years of development in collaboration with users from the pharmaceutical industry within the IMI eTRANSAFE project, which aims, among other objectives, to develop high-quality predictive models based on shared legacy data for assessing the safety of drug candidates., This work has received funding from the eTRANSAFE project (Grant Agreement No. 777365), developed under the Innovative Medicines Initiative Joint Undertaking (IMI2), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects which contributed funding, such as TransQST (No. 116030) as well as the H2020 EU-ToxRisk project (No. 681002) and FAIRplus (No. 802750). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In silico models in drug development: where we are

  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • Sanz, Ferran
The use and utility of computational models in drug development has significantly grown in the last decades, fostered by the availability of high throughput datasets and new data analysis strategies. These in silico approaches are demonstrating their ability to generate reliable predictions as well as new knowledge on the mode of action of drugs and the mechanisms underlying their side effects, altogether helping to reduce the costs of drug development. The aim of this review is to provide a panorama of developments in the field in the last two years., We acknowledge support from ISCIII-FEDER (CPII16/00026), the EU H2020 Programme 2014-2020 under grant agreements no. 681002 (EU-ToxRisk) and no. 676559 (ELIXIR-EXCELERATE), and the IMI2-JU under grants agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE), resources of which are composed of financial contribution from the EU-H2020 and EFPIA companies in kind contribution. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER. The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (ref: MDM-2014-0370).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods

  • Krebs, Alice
  • Pastor Maeso, Manuel
  • Leist, Marcel
Hazard assessment, based on new approach methods (NAM), requires the use of batteries of assays, where individual tests may be contributed by different laboratories. A unified strategy for such collaborative testing is presented. It details all procedures required to allow test information to be usable for integrated hazard assessment, strategic project decisions and/or for regulatory purposes. The EU-ToxRisk project developed a strategy to provide regulatorily valid data, and exemplified this using a panel of > 20 assays (with > 50 individual endpoints), each exposed to 19 well-known test compounds (e.g. rotenone, colchicine, mercury, paracetamol, rifampicine, paraquat, taxol). Examples of strategy implementation are provided for all aspects required to ensure data validity: (i) documentation of test methods in a publicly accessible database; (ii) deposition of standard operating procedures (SOP) at the European Union DB-ALM repository; (iii) test readiness scoring accoding to defined criteria; (iv) disclosure of the pipeline for data processing; (v) link of uncertainty measures and metadata to the data; (vi) definition of test chemicals, their handling and their behavior in test media; (vii) specification of the test purpose and overall evaluation plans. Moreover, data generation was exemplified by providing results from 25 reporter assays. A complete evaluation of the entire test battery will be described elsewhere. A major learning from the retrospective analysis of this large testing project was the need for thorough definitions of the above strategy aspects, ideally in form of a study pre-registration, to allow adequate interpretation of the data and to ensure overall scientific/toxicological validity., This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 681002.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Collaborative SAR modeling and prospective in vitro validation of oxidative stress activation in human HepG2 cells

  • Béquignon, Olivier J. M.
  • Gómez-Tamayo, José C.
  • Lenselink, Eelke B.
  • Wink, Steven
  • Hiemstra, Steven
  • Lam, Chi Chung
  • Gadaleta, Domenico
  • Roncaglioni, Alessandra
  • Norinder, Ulf
  • van de Water, Bob
  • Pastor Maeso, Manuel
  • van Westen, Gerard J. P.
Oxidative stress is the consequence of an abnormal increase of reactive oxygen species (ROS). ROS are generated mainly during the metabolism in both normal and pathological conditions as well as from exposure to xenobiotics. Xenobiotics can, on the one hand, disrupt molecular machinery involved in redox processes and, on the other hand, reduce the effectiveness of the antioxidant activity. Such dysregulation may lead to oxidative damage when combined with oxidative stress overpassing the cell capacity to detoxify ROS. In this work, a green fluorescent protein (GFP)-tagged nuclear factor erythroid 2-related factor 2 (NRF2)-regulated sulfiredoxin reporter (Srxn1-GFP) was used to measure the antioxidant response of HepG2 cells to a large series of drug and drug-like compounds (2230 compounds). These compounds were then classified as positive or negative depending on cellular response and distributed among different modeling groups to establish structure-activity relationship (SAR) models. A selection of models was used to prospectively predict oxidative stress induced by a new set of compounds subsequently experimentally tested to validate the model predictions. Altogether, this exercise exemplifies the different challenges of developing SAR models of a phenotypic cellular readout, model combination, chemical space selection, and results interpretation., This project received funding from the EU-ToxRisk and RISK-HUNT3R projects, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nos. 681002 and 964537, respectively, and was part of the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365 (eTRANSAFE) receiving support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Additional funding was received from the VHP4Safety project, a research project funded by the Netherlands Research Council (NWO) “Netherlands Research Agenda: Research on Routes by Consortia” (NWA-ORC 1292.19.272). The authors declare that this work reflects only the author’s view and that the Innovative Medicines Initiative 2 Joint Undertaking and NWO are not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In vitro teratogenicity testing using a 3D, embryo-like gastruloid system

  • Mantziou, Veronika
  • Baillie-Benson, Peter
  • Jaklin, Manuela
  • Kustermann, Stefan
  • Martinez Arias, Alfonso
  • Moris, Naomi
Pharmaceuticals intended for use in patients of childbearing potential need to be tested for teratogenicity before marketing. Several pharmaceutical companies use animal-free in vitro models which allow a more rapid selection of lead compounds and contribute to 3Rs principles ('replace, reduce and refine') by streamlining the selection of promising compounds submitted to further regulatory studies in animals. Currently available in vitro models typically rely on adherent monolayer cultures or disorganized 3D structures, both of which lack the spatiotemporal and morphological context of the developing embryo. A newly developed 3D 'gastruloid' model has the potential to achieve a more reliable prediction of teratogenicity by providing a robust recapitulation of gastrulation-like events alongside morphological coordination at relatively high-throughput. In this first proof-of-concept study, we used both mouse and human gastruloids to examine a panel of seven reference compounds, with associated in vivo data and known teratogenic risk, to quantitatively assess in vitro teratogenicity. We observed several gross morphological effects, including significantly reduced elongation or decreased size of the gastruloids, upon exposure to several of the reference compounds. We also observed aberrant gene expression using fluorescent reporters, including SOX2, BRA, and SOX17, suggestive of multi-lineage differentiation defects and disrupted axial patterning. Finally, we saw that gastruloids recapitulated some of the known in vivo species-specific susceptibilities between their mouse and human counterparts. We therefore suggest that gastruloids represent a powerful tool for teratogenicity assessment by enabling relevant physiological recapitulation of early embryonic development, demonstrating their use as a novel in vitro teratogenic model system., This work was supported by grants from Medical Research Council (MRC) (MR/R017190/1 and MR/V005367/1) to A.M.A. and N.M., a Leverhulme Trust grant (RPG-2018-356) to AMA, as well as a Gates Cambridge Scholarship awarded to V.M.. The mouse part was supported by an ERC Advanced investigator grant (AdG 834580) to A.M.A. supporting P.B.B. Data derived from human iPSC in vitro model based compound assessment has been supported by the BMBF, EFSA, and the DK-EPA (MST-667-00205) and received funding from the European Union's Horizon 2020 research and innovation program under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX Project

  • Pastor Maeso, Manuel
  • Quintana, Jordi
  • Sanz, Ferran
In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future., The eTOX project (Grant Agreement No. 115002), was developed under the Innovative Medicines Initiative Joint Undertaking (IMI), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects, such as iPiE (no. 115735), TransQST (no. 116030) and eTRANSAFE (no. 777365), as well as the H2020 EU-ToxRisk project (no. 681002)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Computational Approaches for Next-Generation Risk Assessment of Hepatic Toxicity

  • Ortega Vallbona, Rita Carmen
[ES] El daño hepático inducido por fármacos, o DILI (del inglés Drug-Induced Liver Injury), entendido también como el daño hepático causado por la exposición a otros xenobióticos, es una causa frecuente de retirada de fármacos en desarrollo. Las manifestaciones clínicas del DILI van desde el daño hepatocelular o colestático hasta la esteatosis y la fibrosis. Aunque suele resolverse tras la interrupción del tratamiento, el DILI puede progresar a insuficiencia hepática aguda, que puede resultar mortal. La complejidad de las vías biológicas implicadas en el DILI dificulta enormemente su predicción. En la evaluación de riesgos de nueva generación, enfoques relevantes para el ser humano aportan información sobre los mecanismos de toxicidad. Idealmente, estos mecanismos se compilan en redes AOP (del inglés Adverse Outcome Pathway) que conectan los MIEs (del inglés Molecular Initiating Events) y los KEs (del inglés Key Events) con un efecto adverso. En esta tesis se exploran métodos computacionales para incorporar predicciones en una red AOP y reforzar la evidencia durante su desarrollo y transición a una AOP cuantitativa. En el primer capítulo, revisamos ejemplos de enfoques in silico que se han utilizado para abordar diferentes componentes en el AOP de esteatosis, incluyendo modelos (Q)SAR (del inglés (Quantitative) Structure-Avtivity Relationships), read-across, análisis ómicos y métodos basados en modelado molecular. En el segundo capítulo, desarrollamos modelos (Q)SAR para dos tipos de acumulación de lípidos inducida por sustancias químicas, tomando un grupo reducido de ácidos carboxílicos que presentan diferentes efectos en células HepG2 con sólo pequeñas variaciones en su estructura química. En el tercer capítulo, aplicamos modelado molecular para predecir la alteración de MIEs tras la exposición a compuestos. Presentamos un servidor de acoplamiento molecular automatizado, con proteínas preparadas, que permiten simular la unión de un compuesto con una lista de proteínas de interés, ofreciendo la energía de unión y un análisis de las interacciones proteína-ligando, que podría mejorar la clasificación del compuesto introducido como potencial ligando. Este trabajo pretende tender un puente hacia la aplicación de estos métodos computacionales para la evaluación de riesgos de próxima generación, destacando la importancia de la información mecanística y la transparencia de las herramientas, para favorecer su aceptación regulatoria en protocolos informados por AOPs., [CA] El dany hepàtic induït per fàrmacs, o DILI (de l'anglés Drug-Induced Liver Injury), entés també com el dany hepàtic causat per l'exposició altres xenobiòtics, és una causa freqüent de retirada de fàrmacs en desenvolupament. Les manifestacions clíniques del DILI van des del dany hepatocel·lular o colestàtic fins a l'esteatosi o fibrosi. Encara sol resoldre's en interrompre el tractament, el DILI pot progressar a insuficiència hepàtica aguda, que pot resultar mortal. La complexitat de les vies metabòliques implicades en el DILI dificulta enormement la seua predicció. En l'avaluació de riscos de nova generació, enfocaments rellevants per a l'ésser humà oferixen informació sobre els mecanismes de toxicitat. Idealment, estos mecanismes es compilen en xarxes AOP (de l'anglés Adverse Outcome Pathway) que connecten els MIEs (de l'anglés Molecular Initiating Events) i els KEs (de l'anglés Key Events) amb un efecte advers. En esta tesi s'exploren mètodes computacionals per a incorporar prediccions en una xarxa AOP i reforçar l'evidència durant el seu desenvolupament i transició a una AOP quantitativa. En el primer capítol, revisem exemples d'aproximacions in silico que s'han utilitzat per a abordar diferents components en l'AOP d'esteatosi, que inclouen models (Q)SAR (de l'anglés (Quantitative) Structure-Avtivity Relationships), read-across, anàlisis òmics i mètodes basats en modelatge molecular. En el segon capítol, desenvolupem models (Q)SAR per a dos tipus d'acumulació de lípids induïda per substàncies químiques, prenent un grup reduït d'àcids carboxílics que presenten diferents efectes en cèl·lules HepG2 amb només xicotetes variacions en la seua estructura química. En el tercer capítol, apliquem modelat molecular per a predir l'alteració de MIEs per exposició a compostos. Presentem un servidor d'acoblament molecular automatitzat, amb proteïnes preparades, que permeten simular la unió d'un compost amb una llista de proteïnes d'interés, oferint l'energia d'unió i una anàlisi de les interaccions proteïna-lligand, que podria millorar la classificació del compost introduït com a potencial lligand. Este treball pretén bastir un pont cap a l'aplicació d'estos mètodes computacionals per a l'avaluació de riscos de pròxima generació, destacant la importància de la informació mecanística i la transparència de les ferramentes, per a afavorir l'acceptació reguladora d'estes metodologies per al seu ús en protocols informats per AOPs., [EN] Drug-induced liver injury (DILI), understood as liver damage caused by exposure to drugs or other xenobiotics, is one of the main reasons for drug attrition. The clinical manifestations of DILI range from hepatocellular and cholestatic damage to steatosis and fibrosis. While most cases of DILI resolve after discontinuation, it can progress to life-threatening conditions, such as acute liver failure. The network of biological pathways that can lead to the appearance of DILI is very complex and involves numerous mechanisms, making the prediction of DILI extremely difficult. In the context of next-generation risk assessment, the use of human-relevant approaches offers insights into the mechanisms of toxicity. The knowledge about these mechanisms is ideally gathered into Adverse Outcome Pathway (AOP) networks that connect Molecular Initiating Events (MIEs) and Key Events (KEs) to an adverse outcome. In this thesis, we explore several computational methodologies that can be used to input data predictions into an AOP network to add to the weight of evidence during its development and transition to a quantitative AOP. In the first chapter, we review examples of in silico approaches that have been used to address different building blocks in the steatosis AOP, including (Quantitative) Structure-Activity Relationships ((Q)SAR) models, read-across, omics analysis, and structure-based methods. In the second chapter, we develop (Q)SAR models for two types of chemical-induced lipid accumulation, taking a small group of carboxylic acids that present different effects in HepG2 cells with only small variations in their chemical structure. In the third chapter, we switch to the use of structure-based methods for the prediction of MIE alteration by exposure to compounds. We explain how we have developed an automated docking server with prepared protein structures that allow for the binding of query compounds to the set of proteins of interest and not only offer the binding energy as a result but also analyse the protein-ligand interactions and use that to add information that could lead to a better classification of the query compounds as binders or non-binders. Overall, the work presented here intends to bridge the application of computational approaches for next-generation risk assessment. By emphasizing the importance of mechanistic information and tool transparency, this work aims to aid in advancing the regulatory acceptance of these approaches to be used in AOP-informed hazard assessment pipelines., This work was performed as part of the ASPIS cluster (https://aspis-cluster.eu/), funded by the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements No 963845 (ONTOX, https://ontox-project.eu/), No 965406 (PrecisionTox, https://precisiontox.org/), and No 964537 (RISK-HUNT3R, https://www.risk-hunt3r.eu/). This work also received support from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 681002 (EU-ToxRisk) and from CIBERHED (Spain). In addition, this work was funded by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union, through grant PI21/00223. We gratefully acknowledge the financial support of the Agencia Valenciana de la Investigación (AVI, https://innoavi.es/en/) through its Innodocto programme (reference numbers INNTA3/2022/13 and INNTA3/2021/14), financed by the European Union through the European Regional Development Fund (ERDF) programme 2021–2027 Comunitat Valenciana. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 872195 (MSCA-RISE “VIDEC”). The Swedish Research Council (Vetenskapsrådet) and the Swedish Cancer Foundation are gratefully acknowledged for funding (LAE). Allocation of supercomputing time at C3SE (Gothenburg) and NSC (Linköping) was provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS), partially funded by the Swedish Research Council through grant agreement No 2022-06725.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Uncovering the toxicity mechanisms of a series of carboxylic acids in liver cells through computational and experimental approaches

  • Ortega-Vallbona, Rita
  • Méndez, Rebeca
  • Tolosa, Laia
  • Escher, Sylvia E.
  • Castell, José V.
  • Gozalbes, Rafael
  • Serrano-Candelas, Eva
[EN] Hepatotoxicity poses a significant concern in drug design due to the potential liver damage that can be caused by new drugs. Among common manifestations of hepatotoxic damage is lipid accumulation in hepatic tissue, resulting in liver steatosis or phospholipidosis. Carboxylic derivatives are prone to interfere with fatty acid metabolism and cause lipid accumulation in hepatocytes. This study investigates the toxic behaviour of 24 structurally related carboxylic acids in hepatocytes, specifically their ability to cause accumulation of fatty acids and phospholipids. Using high-content screening (HCS) assays, we identified two distinct lipid accumulation patterns. Subsequently, we developed structure-activity relationship (SAR) and quantitative structure-activity relationship (QSAR) models to determine relevant molecular substructures and descriptors contributing to these adverse effects. Additionally, we calculated physicochemical properties associated with lipid accumulation in hepatocytes and examined their correlation with our chemical structure characteristics. To assess the applicability of our findings to a wide range of chemical compounds, we employed two external datasets to evaluate the distribution of our QSAR descriptors. Our study highlights the significance of subtle molecular structural variations in triggering hepatotoxicity, such as the presence of nitrogen or the specific arrangement of substitutions within the carbon chain. By employing our comprehensive approach, we pinpointed specific molecules and elucidated their mechanisms of toxicity, thus offering valuable insights to guide future toxicology investigations., The authors wish to acknowledge the support of the European Union's Horizon 2020 research and innovation program under Grant Agreement No 681002 (EU-ToxRisk) and CIBERHED (Spain) . This work has also been funded by Instituto de Salud Carlos III (ISCIII) (co-funded by the European Union) through grant PI21/00223. We gratefully acknowledge the financial support of the Agencia Valenciana de la Investigacion (AVI, https://innoavi.es/en/) by its program Innodocto (Reference number INNTA3/2021/14).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Collaborative SAR modeling and prospective in vitro validation of oxidative stress activation in human HepG2 cells

  • Béquignon, Olivier J. M.
  • Gómez-Tamayo, José C.
  • Lenselink, Eelke B.
  • Wink, Steven
  • Hiemstra, Steven
  • Lam, Chi Chung
  • Gadaleta, Domenico
  • Roncaglioni, Alessandra
  • Norinder, Ulf
  • van de Water, Bob
  • Pastor Maeso, Manuel
  • van Westen, Gerard J. P.
Oxidative stress is the consequence of an abnormal increase of reactive oxygen species (ROS). ROS are generated mainly during the metabolism in both normal and pathological conditions as well as from exposure to xenobiotics. Xenobiotics can, on the one hand, disrupt molecular machinery involved in redox processes and, on the other hand, reduce the effectiveness of the antioxidant activity. Such dysregulation may lead to oxidative damage when combined with oxidative stress overpassing the cell capacity to detoxify ROS. In this work, a green fluorescent protein (GFP)-tagged nuclear factor erythroid 2-related factor 2 (NRF2)-regulated sulfiredoxin reporter (Srxn1-GFP) was used to measure the antioxidant response of HepG2 cells to a large series of drug and drug-like compounds (2230 compounds). These compounds were then classified as positive or negative depending on cellular response and distributed among different modeling groups to establish structure-activity relationship (SAR) models. A selection of models was used to prospectively predict oxidative stress induced by a new set of compounds subsequently experimentally tested to validate the model predictions. Altogether, this exercise exemplifies the different challenges of developing SAR models of a phenotypic cellular readout, model combination, chemical space selection, and results interpretation., This project received funding from the EU-ToxRisk and RISK-HUNT3R projects, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nos. 681002 and 964537, respectively, and was part of the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365 (eTRANSAFE) receiving support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Additional funding was received from the VHP4Safety project, a research project funded by the Netherlands Research Council (NWO) “Netherlands Research Agenda: Research on Routes by Consortia” (NWA-ORC 1292.19.272). The authors declare that this work reflects only the author’s view and that the Innovative Medicines Initiative 2 Joint Undertaking and NWO are not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX Project

  • Pastor Maeso, Manuel
  • Quintana, Jordi
  • Sanz, Ferran
In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future., The eTOX project (Grant Agreement No. 115002), was developed under the Innovative Medicines Initiative Joint Undertaking (IMI), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects, such as iPiE (no. 115735), TransQST (no. 116030) and eTRANSAFE (no. 777365), as well as the H2020 EU-ToxRisk project (no. 681002)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Flame: an open source framework for model development, hosting, and usage in production environments

  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Sanz, Ferran
This article describes Flame, an open source software for building predictive models and supporting their use in production environments. Flame is a web application with a web-based graphic interface, which can be used as a desktop application or installed in a server receiving requests from multiple users. Models can be built starting from any collection of biologically annotated chemical structures since the software supports structural normalization, molecular descriptor calculation, and machine learning model generation using predefined workflows. The model building workflow can be customized from the graphic interface, selecting the type of normalization, molecular descriptors, and machine learning algorithm to be used from a panel of state-of-the-art methods implemented natively. Moreover, Flame implements a mechanism allowing to extend its source code, adding unlimited model customization. Models generated with Flame can be easily exported, facilitating collaborative model development. All models are stored in a model repository supporting model versioning. Models are identified by unique model IDs and include detailed documentation formatted using widely accepted standards. The current version is the result of nearly 3 years of development in collaboration with users from the pharmaceutical industry within the IMI eTRANSAFE project, which aims, among other objectives, to develop high-quality predictive models based on shared legacy data for assessing the safety of drug candidates., This work has received funding from the eTRANSAFE project (Grant Agreement No. 777365), developed under the Innovative Medicines Initiative Joint Undertaking (IMI2), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects which contributed funding, such as TransQST (No. 116030) as well as the H2020 EU-ToxRisk project (No. 681002) and FAIRplus (No. 802750). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In vitro teratogenicity testing using a 3D, embryo-like gastruloid system

  • Mantziou, Veronika
  • Baillie-Benson, Peter
  • Jaklin, Manuela
  • Kustermann, Stefan
  • Martinez Arias, Alfonso
  • Moris, Naomi
Pharmaceuticals intended for use in patients of childbearing potential need to be tested for teratogenicity before marketing. Several pharmaceutical companies use animal-free in vitro models which allow a more rapid selection of lead compounds and contribute to 3Rs principles ('replace, reduce and refine') by streamlining the selection of promising compounds submitted to further regulatory studies in animals. Currently available in vitro models typically rely on adherent monolayer cultures or disorganized 3D structures, both of which lack the spatiotemporal and morphological context of the developing embryo. A newly developed 3D 'gastruloid' model has the potential to achieve a more reliable prediction of teratogenicity by providing a robust recapitulation of gastrulation-like events alongside morphological coordination at relatively high-throughput. In this first proof-of-concept study, we used both mouse and human gastruloids to examine a panel of seven reference compounds, with associated in vivo data and known teratogenic risk, to quantitatively assess in vitro teratogenicity. We observed several gross morphological effects, including significantly reduced elongation or decreased size of the gastruloids, upon exposure to several of the reference compounds. We also observed aberrant gene expression using fluorescent reporters, including SOX2, BRA, and SOX17, suggestive of multi-lineage differentiation defects and disrupted axial patterning. Finally, we saw that gastruloids recapitulated some of the known in vivo species-specific susceptibilities between their mouse and human counterparts. We therefore suggest that gastruloids represent a powerful tool for teratogenicity assessment by enabling relevant physiological recapitulation of early embryonic development, demonstrating their use as a novel in vitro teratogenic model system., This work was supported by grants from Medical Research Council (MRC) (MR/R017190/1 and MR/V005367/1) to A.M.A. and N.M., a Leverhulme Trust grant (RPG-2018-356) to AMA, as well as a Gates Cambridge Scholarship awarded to V.M.. The mouse part was supported by an ERC Advanced investigator grant (AdG 834580) to A.M.A. supporting P.B.B. Data derived from human iPSC in vitro model based compound assessment has been supported by the BMBF, EFSA, and the DK-EPA (MST-667-00205) and received funding from the European Union's Horizon 2020 research and innovation program under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods

  • Krebs, Alice
  • Pastor Maeso, Manuel
  • Leist, Marcel
Hazard assessment, based on new approach methods (NAM), requires the use of batteries of assays, where individual tests may be contributed by different laboratories. A unified strategy for such collaborative testing is presented. It details all procedures required to allow test information to be usable for integrated hazard assessment, strategic project decisions and/or for regulatory purposes. The EU-ToxRisk project developed a strategy to provide regulatorily valid data, and exemplified this using a panel of > 20 assays (with > 50 individual endpoints), each exposed to 19 well-known test compounds (e.g. rotenone, colchicine, mercury, paracetamol, rifampicine, paraquat, taxol). Examples of strategy implementation are provided for all aspects required to ensure data validity: (i) documentation of test methods in a publicly accessible database; (ii) deposition of standard operating procedures (SOP) at the European Union DB-ALM repository; (iii) test readiness scoring accoding to defined criteria; (iv) disclosure of the pipeline for data processing; (v) link of uncertainty measures and metadata to the data; (vi) definition of test chemicals, their handling and their behavior in test media; (vii) specification of the test purpose and overall evaluation plans. Moreover, data generation was exemplified by providing results from 25 reporter assays. A complete evaluation of the entire test battery will be described elsewhere. A major learning from the retrospective analysis of this large testing project was the need for thorough definitions of the above strategy aspects, ideally in form of a study pre-registration, to allow adequate interpretation of the data and to ensure overall scientific/toxicological validity., This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 681002.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

New approach methods (NAMs) supporting read-across: Two neurotoxicity AOP-based IATA case studies

  • Van der Stel, Wanda
  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Van de Water, Bob
Read-across approaches are considered key in moving away from in vivo animal testing towards addressing data-gaps using new approach methods (NAMs). Ample successful examples are still required to substantiate this strategy. Here we present and discuss the learnings from two OECD IATA endorsed read-across case studies. They involve two classes of pesticides – rotenoids and strobilurins – each having a defined mode-of-action that is assessed for its neurological hazard by means of an AOP-based testing strategy coupled to toxicokinetic simulations of human tissue concentrations. The endpoint in question is potential mitochondrial respiratory chain mediated neurotoxicity, specifically through inhibition of complex I or III. An AOP linking inhibition of mitochondrial respiratory chain complex I to the degeneration of dopaminergic neurons formed the basis for both cases but was deployed in two different regulatory contexts. The two cases also exemplify several different read-across concepts: analogue versus category approach, consolidated versus putative AOP, positive versus negative prediction (i.e., neurotoxicity versus low potential for neurotoxicity), and structural versus biological similarity. We applied a range of NAMs to explore the toxicodynamic properties of the compounds, e.g., in silico docking as well as in vitro assays and readouts – including transcriptomics – in various cell systems, all anchored to the relevant AOPs. Interestingly, although some of the data addressing certain elements of the read-across were associated with high uncertainty, their impact on the overall read-across conclusion remained limited. Coupled to the elaborate regulatory review that the two cases underwent, we propose some generic learnings of AOP-based testing strategies supporting read-across., This work was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 681002 (EU-ToxRisk). Parts of this work contributed to two IATA Case Studies Projects “Identification and characterization of parkinsonian hazard liability of deguelin by an AOP-based testing and read across approach” and “Mitochondrial complex-III-mediated neurotoxicity of azoxystrobin – Read-across to other strobilurins” (van der Stel et al., 2020b; Bennekou et al., 2020).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In silico models in drug development: where we are

  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • Sanz, Ferran
The use and utility of computational models in drug development has significantly grown in the last decades, fostered by the availability of high throughput datasets and new data analysis strategies. These in silico approaches are demonstrating their ability to generate reliable predictions as well as new knowledge on the mode of action of drugs and the mechanisms underlying their side effects, altogether helping to reduce the costs of drug development. The aim of this review is to provide a panorama of developments in the field in the last two years., We acknowledge support from ISCIII-FEDER (CPII16/00026), the EU H2020 Programme 2014-2020 under grant agreements no. 681002 (EU-ToxRisk) and no. 676559 (ELIXIR-EXCELERATE), and the IMI2-JU under grants agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE), resources of which are composed of financial contribution from the EU-H2020 and EFPIA companies in kind contribution. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER. The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (ref: MDM-2014-0370).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Determination of benchmark concentrations and their statistical uncertainty for cytotoxicity test data and functional in vitro assays

  • Krebs, Alice
  • Nyffeler, Johanna
  • Karreman, Christiaan
  • Schmidt, Béla Z.
  • Kappenberg, Franziska
  • Mellert, Jan
  • Pallocca, Giorgia
  • Pastor Maeso, Manuel
  • Rahnenführer, Jörg
  • Leist, Marcel
Many toxicological test methods, including assays of cell viability and function, require an evaluation of concentration-response data. This often involves curve fitting, and the resulting mathematical functions are then used to determine the concentration at which a certain deviation from the control value occurs (e.g. a decrease of cell viability by 15%). Such a threshold is called the benchmark response (BMR). For a toxicological test, it is often of interest to determine the concentration of test compound at which a pre-defined BMR of e.g. 10, 25 or 50% is reached. The concentration at which the modelled curve crosses the BMR is called the benchmark concentration (BMC). We present a user-friendly, web-based tool (BMCeasy), designed for operators without programming skills and profound statistical background, to determine BMCs and their confidence intervals. BMCeasy allows simultaneous analysis of viability plus a functional test endpoint, and it yields absolute BMCs with confidence intervals for any BMR. Besides an explanation of the algorithm underlying BMCeasy, this article also gives multiple examples of data outputs. BMCeasy was used within the EU-ToxRisk project for preparing data packages that were submitted to regulatory authorities, demonstrating the real-life applicability of the tool., This work was supported by the BMBF, EFSA, the DK-EPA, and the DFG (Konstanz Research School of Chemical Biology; KoRS-CB). It has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements No. 681002 (EU-ToxRisk) and No. 825759 (ENDpoiNTs). We are grateful to collaborators R. von Hellfeld and T. Braunbeck (University of Heidelberg), and H. Vrieling and J. Boei (Leiden University Medical Center) of the EU-ToxRisk con-sortium for providing the experimental data. We are indebted to S. Förster for triggering this work and to other colleagues for in-sightful discussions.